Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Gilead Sciences, WHO expand visceral leishmaniasis collaboration with 400K AmBisome doses, $9.2M support
Donation agreement, infectious disease, small molecule, commercialization - Read more

United Immunity acquires macrophage assets from Carisma Therapeutics for cancer and liver fibrosis treatment
Acquisition, oncology, cell therapy, rare disease, drug discovery - Read more

Degron Therapeutics, MSD collaborate to jointly advance molecular glue degrader candidates in oncology
Co-development, oncology, small molecule, drug discovery, R&D - Read more

Calico Life Sciences, Nexo Therapeutics collaborate to discover small molecule therapies for age-related diseases
Research collaboration, small molecule, aging/age-related disease, drug discovery, co-development - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) plus Keytruda cuts progression risk 65% in Ph3 non-small cell lung cancer
Antibody-drug conjugate, cancer, small molecule, non-small cell lung cancer, TROP2, combination therapy - Read more

Infex Therapeutics' (INFEX702) anti-PcrV antibody advances after Ph2a in non-cystic fibrosis bronchiectasis
Antibody, infectious disease, monoclonal antibody, non-cystic fibrosis bronchiectasis, Pseudomonas aeruginosa - Read more

Eli Lilly's (retatrutide) Ph3 TRIUMPH-1 delivers bariatric surgery–level weight loss in obesity patients
Small molecule, metabolic, obesity, triple hormone receptor agonist, GLP-1, incretin - Read more

BioNTech and Bristol Myers Squibb's pumitamig (BNT327) Ph2 data show 70% response rate in advanced non-small-cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF, combination therapy - Read more

Sobi's (pozdeutinurad) meets primary endpoint in Ph3 study for uncontrolled gout
Small molecule, metabolic, URAT1 inhibitor, gout, uric acid reduction - Read more

Research Alliance III raises $75M SPAC IPO, targeting China-based biotech merger
Biotech SPAC, drug development, diagnostics, healthcare technology, services - Read more

Dandelion Health raises $14M Series A, advancing clinical intelligence platform for pharma drug development
Clinical intelligence platform, data analytics, biomarker discovery, real-world evidence, drug development - Read more

Liminatus Pharma acquires CAR-T biotech InnocsAI for $320M in stock to expand oncology pipeline
CAR-T, oncology, major transaction, strategic, financial - Read more

Medtronic to acquire SPR Therapeutics for $650M, expanding minimally invasive chronic pain therapy portfolio
Neuromodulation device, chronic pain, major transaction, strategic - Read more

Dr. Reddy's Laboratories launches oral semaglutide biosimilar Obeda in India for type 2 diabetes
Biosimilar, type 2 diabetes, competitive, revenue impact - Read more

Scribe Therapeutics gains Australian TGA clearance to begin first-in-human trial of STX-1150 for LDL-C reduction
Gene editing, cardiovascular, regulatory, first-in-human - Read more

Moderna's mFLUSIVA (mRNA-1010) to face FDA advisory panel review for influenza prevention in adults 50 and older
Vaccine, infectious disease, mRNA vaccine, influenza - Read more

Amgen's Tavneos resumes new patient starts in Japan after label update addressing liver injury warnings
Small molecule, autoimmune, regulatory, rare disease - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Biogen, Denali Therapeutics' BIIB122 (DNL151) fails Ph2b trial in idiopathic Parkinson's disease, halting development
Small molecule, neurological, LRRK2 inhibitor, Parkinson's disease, kinase inhibitor - Read more

Eli Lilly sues church-linked pharmacies, wholesalers over $200M+ Trulicity rebate fraud scheme
Small molecule, diabetes, fraud, financial - Read more

NIH's NIAID acting director Jeffery Taubenberger steps down amid Senate budget hearing, deepening leadership vacuum
Infectious disease, leadership, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here